Highly Innovative Drug Program in the Czech Republic: Description and Pharmacoeconomic Results—Cost-Effectiveness and Budget Impact Analyses

ConclusionsThis analysis provides better insight into the HID program for costly innovative drugs over a 10-year follow-up. A successful transition to PR status was observed for most of the HIDs (83%).
Source: Value in Health Regional Issues - Category: International Medicine & Public Health Source Type: research